Elicio Therapeutics will deliver a company presentation on Thursday, May 14, 2026 at 12:20 PM ET during the Bank of America Healthcare Conference in Las Vegas. CEO Robert Connelly will be joined by EVP of R&D Christopher Haqq, MD, PhD, CSO Pete DeMuth, PhD, and CSFO Preetam Shah for the live webcast, which will be available on Elicio’s Events page for 90 days thereafter. Investors interested in arranging one-on-one meetings can contact their Bank of America representative.

Elicio’s lead off-the-shelf immunotherapy, ELI-002 7P, targets the most common KRAS mutations driving roughly 25% of solid tumors, including pancreatic and colorectal cancers. In the AMPLIFY-201 Phase 1 study, the full patient population achieved a median 16.3-month recurrence-free survival and a 28.9-month median overall survival, underscoring the potential durability of the AMP technology.

The company plans to advance ELI-002 7P into adjuvant, neoadjuvant and metastatic settings for pancreatic ductal adenocarcinoma and other mKRAS-positive cancers. Off-the-shelf manufacturing promises lower costs and rapid drug availability for high-risk and neo-adjuvant patients, supporting Elicio’s strategy to scale commercial production swiftly upon regulatory approval.